Market Intelligence, Emerging Pipeline, and High-Purity Reagents for NET-Mediated Metastasis Inhibition.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CCDC25 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCDC25 Full-Length & Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (native folding). |
View CCDC25 Products |
| Benchmark Ab | Anti-CCDC25 Reference mAb (Preclinical Surrogate) Sequence-defined recombinant positive control for assay benchmarking. |
View CCDC25 Products |
| Gene Delivery | CCDC25 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for membrane translocation assays. |
View CCDC25 Products |
| Validator | CCDC25 siRNA Set For knockdown verification and specificity controls in migration assays. |
View CCDC25 Products |
| Related Target: ILK | ILK (Integrin-Linked Kinase) Recombinant Protein Validated binding partner for CCDC25 signal transduction studies. |
View ILK Products |
| Related Target: PAD4/PADI4 | PAD4 Recombinant Protein Key NETosis regulator. Functional control for NET-derived DNA sensing pathways. |
View PAD4 Products |
| Related Target: Rac1 | Rac1 Recombinant Protein Downstream GTPase in CCDC25-mediated migration signaling. |
View RAC1 Products |
| Related Target: LCP1 | LCP1 (Plastin-2) Recombinant Protein Downstream cytoskeletal signaling partner in metastasis. |
View LCP1 Products |
| Related Target: TLR9 | TLR9 Recombinant Protein Endosomal DNA sensor for pathway cross-talk and counter-screening. |
View TLR9 Products |
| Related Target: ELANE | ELANE (Neutrophil Elastase) Recombinant Protein Critical marker of NETs that bind CCDC25. |
View ELANE Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| DNA-Binding Specificity Validation | Full-length CCDC25 with intact N-terminal DNA-binding domain. Sequence Verified. High purity (>95%) for EMSA/SPR assays. Mutant panel (DNA-binding domain deletion) available. |
| Native Coiled-Coil Folding & Oligomerization | HEK293 Expressed Full-Length Protein with theoretical MW verified by SEC; Endotoxin Controlled (<1EU/ug). |
| Ligand Blocking / NET-DNA Interaction | HEK293 expressed ECD-Fc fusion proteins ensuring proper conformational presentation of the DNA-binding domain. |
| Intracellular Localization Studies | Lentivirus particles for stable CCDC25 expression. Suitable for live-cell imaging of membrane translocation upon DNA stimulation. |
| Protein-Protein Interaction (CCDC25-ILK) | Co-expression systems available. High-purity ILK protein for binding assays and crystallography. |
| Lack of Reference Standard | Sequence-Defined Recombinant Reference Antibody included for assay qualification. |
| Off-Target Cross-Reactivity / False Positives | Validated siRNA sets included for orthogonal knockdown verification in directional migration assays. |
Live CCDC25 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
Discovered as a critical mediator of neutrophil extracellular trap (NET)-driven metastasis, CCDC25 represents a frontier first-in-class target in cancer biology. The race for CCDC25 therapeutics is intensifying, with major players shifting focus from traditional cytotoxic agents to selective NET pathway inhibitors. As first-generation small molecules and neutralizing antibodies enter preclinical development, the next wave of R&D is targeting combination strategies with standard-of-care chemotherapy and immune checkpoint inhibitors to prevent treatment-induced metastasis. Key areas include protein-protein interactions (CCDC25-ILK) and intracellular DNA sensing mechanisms.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAb | Discovery-stage biotechs & academia | Liver Metastasis, Breast & Colon Cancers | DNA-binding blockade assay (Need native full-length protein for SPR/EMSA) |
| Blocking Peptide / Peptide-Fc | Early therapeutic platforms | Adjuvant Metastasis Prevention | Epitope mapping (Need mutant protein panel) |
| Small Molecule Inhibitor | Structural biology consortia | Advanced Metastatic Cancer (Gastric, Pancreatic) | High-throughput DNA competition screen (Need full-length protein with native conformation) |
| siRNA / mRNA Therapy | Academic & translation labs | Metastatic Solid Tumors, Residual Disease | Knockdown validation (Need potent siRNA & lentiviral ORF for stable cell lines) |
| Protein Degrader (PROTAC) | Targeted protein degradation companies | Refractory Metastatic Cancer | Intracellular Localization Assay (Need lentivirus for live-cell E3 ligase recruitment) |